Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
#4187 Psychiatric and cognitive function in patients with serotonin producing neuroendocrine tumors
Introduction: Cognitive and psychiatric problems are common in cancer patients, but literature in patients with neuroendocrine tumors (NET) is scarce. Peripheral serotonin overproduction by the tumor, clinically manifesting as carcinoid syndrome, is hypothesized to be related to cognitive and psychiatric problems, through depletion of serotonin’s precursor tryptophan.
Conference:
Presenting Author: Tesselaar M
Authors: Luijendijk M, Tesselaar M, van Rossum H, Korse C, Verbeek W,
Keywords: Neuroendocrine neoplasm, carcinoid syndrome, cognitive functioning, depression, anxiety, serotonin, tryptophan, 5-HIAA,
Introduction: Since 2019 the Global Leadership Into Malnutrition (GLIM) criteria exist for diagnosing malnutrition. Patients (pts) with gastoenteropancreatic (GEP) neuroendocrine tumors (NETs) treated with somatostatin analogues (SSAs) are at risk of malnutrition. Deficiencies in fat-soluble vitamins, minerals and trace elements (micronutrients) are not part of the GLIM criteria but frequently reported in pts with GEP-NETs treated with SSAs.
Conference:
Presenting Author: Clement D
Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,
Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,
Introduction: Patients (pts) with GEP-NETs treated with somatostatin analogues (SSA’s) are at risk of malnutrition. This has been reported, using weight loss or body mass index (BMI) only. The Global leadership into malnutrition (GLIM) criteria include weight loss, BMI and sarcopenia. In pts with other types of cancer the presence of malnutrition, has a negative effect on overall survival (OS). In pts with GEP-NETs treated with SSA’s this has not been explored before.
Conference:
Presenting Author: Clement D
Authors: Clement D, van Leerdam M, Tesselaar M, Cananea E, Martin W,
Keywords: gastroenteropancreatic neuroendocrine tumor, somatostatin analogue, malnutrition, sarcopenia, survival,
Introduction: Well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are characterized by high-density expression of somatostatin receptors (SSTRs). RYZ101 (225Ac-DOTATATE) is a highly potent alpha-emitting radiopharmaceutical therapy (RPT) being developed for SSTR+ solid tumors. ACTION-1 is a 2-part, global, randomized, controlled, open-label, Phase 1b/3 trial of RYZ101. Part 1 (Phase 1b), an uncontrolled dose de-escalation study, is complete with no dose-limiting toxicities.
Conference:
Presenting Author: Singh S
Authors: Singh S, Tesselaar M, Strosberg J, Jacene H, Halperin D,
Keywords: RYZ101, Gastroenteropancreatic neuroendocrine tumor, Somatostatin receptor, Radiopharmaceutical therapy,
Introduction: Appendiceal goblet cell carcinomas (aGCC) present with overlapping features of appendiceal neuroendocrine neoplasms (ANET) and adenocarcinomas. A previous study found that ANET with peritoneal metastases have a 5-year survival rate of 7%. Recent studies show that ANET rarely metastasizes, contrary to aGCC. The latest WHO classification excluded aGCC from the group of NETs and classified it as appendiceal adenocarcinomas.
Conference:
Presenting Author: Dijke K
Authors: Dijke K, Levy S, van den Berg J, Tesselaar M,
Keywords: Goblet cell carcinoma, Appendiceal neuroendocrine tumor, Survival,